Trial Profile

Pyrotinib Maleate With or Without Trastuzumab in the Treatment of HER2-positive Advanced Colorectal Cancer: a Multicenter Clinical Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pyrotinib (Primary) ; Trastuzumab (Primary)
Indications Colorectal cancer
Focus Therapeutic Use

Most Recent Events

13 Jul 2021 Planned primary completion date changed from 17 Jun 2021 to 17 Dec 2021.
08 Jun 2021 Preliminary results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
07 Feb 2021 Study design changed to Single Group Assignment. Masking changed to Open Label. Allocation changed to Non-Randomized.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com